RxDoctor Payments Data

Thomas Buzbee, MD

Internal Medicine · Tyler, TXNPI 1770682619

Payments from drug & device makers

$249,338in general payments, 2019–2025

Across 1,043 payments — averaging $239.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$104K
  • American Regent$73K
  • Esperion Therapeutics, Inc.$47K
  • Regeneron$14K
  • Sanofi-aventis U.S. LLC$4K
  • AbbVie$2K
  • plus $6K from 45 others

What the payments were for

  • Speaking & faculty fees$102,12888%
  • Travel & lodging$1,5491%
  • Food & beverage$12,40311%
  • Education$1320%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$249,338 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$1,656,723
Medicare patients
1,955
Services billed
52,438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide570$671,264
EliquisApixaban829$465,806
Repatha SureclickEvolocumab280$189,778
MounjaroTirzepatide158$184,979
JardianceEmpagliflozin211$161,234
XareltoRivaroxaban243$158,532
FarxigaDapagliflozin Propanediol172$142,650
Trelegy ElliptaFluticasone/Umeclidin/Vilanter101$90,834
MyrbetriqMirabegron158$71,561
TrulicityDulaglutide50$70,881
JanuviaSitagliptin Phosphate79$70,426
NuedextaDextromethorphan Hbr/Quinidine85$70,302
RybelsusSemaglutide72$55,741
RexultiBrexpiprazole45$52,968
Repatha SyringeEvolocumab79$50,571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,239$727,005642 claims
PfizerEliquis$926$465,806829 claims
Lilly USA, LLCMounjaro, Trulicity$66$255,860208 claims
Johnson & JohnsonXarelto, Invokana$110$182,536278 claims
Boehringer IngelheimJardiance$47$161,234211 claims
AstraZenecaFarxiga$86$142,650172 claims
MerckJanuvia, Janumet, Janumet Xr$738$110,842145 claims
GSKTrelegy Ellipta, Breo Ellipta$125$109,857127 claims
Astellas Pharma US IncMyrbetriq$278$71,561158 claims
Otsuka America Pharmaceutical, Inc.Rexulti$14$52,96845 claims
AbbVieLinzess$1,619$46,45058 claims
Sanofi-aventis U.S. LLCMultaq$3,922$39,08255 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →